| Literature DB >> 29507706 |
Helena U Westergren1,2, Li-Ming Gan1,3, Marianne Månsson3,4, Sara Svedlund1,5.
Abstract
BACKGROUND: The impact of personalized exercise training and a healthy dietary lifestyle in healthy volunteers on coronary flow reserve and cardiovascular function remains to be investigated in a controlled study setting.Entities:
Keywords: coronary flow reserve; microvascular dysfunction; physical exercise; ultrasound
Year: 2018 PMID: 29507706 PMCID: PMC5823634 DOI: 10.18632/oncotarget.23958
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Baseline characteristics of study cohort
| Whole study population ( | |
|---|---|
| Male (number, %) | 53 (19) |
| Age (years) | 54 ± 6 |
| Body mass index (kg/m2) | 24.0 (23.0;25.0) |
| Waist/Hip ratio ( | 0.85 (0.81;0.89) |
| Fat percentage (%) ( | 29.7 (27.2;32.9) |
| SBP (mmHg) | 118 (110;125) |
| DBP (mmHg) | 70 (70;80) |
| Maximal exercise capacity (W) | 162 ± 45 |
| LVEF (%) | 65 ± 7 |
| Cardiac Output (102) | 35 (33;43) |
| Heart rate (bpm) | 61 ± 10 |
| Total cholesterol (mmol/L) ( | 5.4 ± 0.9 |
| Triglycerides (mmol/L) ( | 0.77 (0.58;1.05) |
| HDL (mmol/L) ( | 1.85 (1.5;2.23) |
| Fasting Glucose (mmol/L) ( | 5.2 ± 0.4 |
| Insulin (mU/L) ( | 4.6 (3.1;6.5) |
| HOMA-IR ( | 1.1 (0.7;1.6) |
Data are presented with mean ± SD or median ± interquartile range for normally distributed and non-normally distributed, respectively. DBP = diastolic blood pressure; HDL=high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; LVEF = left ventricle ejection fraction; SBP = systolic blood pressure.
Figure 2Study design
Schematic overview of study design. Subjects were randomized into DAPS with a three months intervention period as well as a standard group including a three months control period followed by a three months standard exercise period. The primary objective of the current study was to compare effects of the DAPS program (A) including personalized exercise training and Mediterranean-inspired diet with a time-aligned initial control period of the standard group (B). Secondary objective was to compare the DAPS program (A) with the standard program (C), mimicking a regular gym and Mediterranean-inspired nutrition program. Finally, the third objective was to compare the standard program (C) with its own control period (B). DAPS = Diagnosis, Analysis, Personalization, Supervision.
Figure 3Change in coronary flow reserve and hyperemic left ventricle function after a personalized supervised health intervention program
The number of 36 healthy inactive volunteers were recruited for study participation and randomized into a three months DAPS program (n = 19) or a three months control period followed by three months standard intervention program (n = 17). (A) Shows the increase in CFR after DAPS intervention compared to controls, p = 0.005. (B) Displays the amelioration in hyperemic left ventricle ejection fraction in the DAPS group compared to controls, p = 0.022. Data are presented with mean ± SD. CFR = coronary flow reserve; DAPS = Diagnosis, Analysis, Personalization, Supervision; LVEF = Left Ventricle Ejection Fraction.
Effect of personalized overall health program on physiological testing in DAPS compared to controls using ANCOVA
| DAPS pre-exercise ( | DAPS post-exercise ( | Standard pre-control ( | Standard post-control = pre-exercise ( | Adjusted effect (%) (95% CI) | ||
|---|---|---|---|---|---|---|
| Basal flow (cm/s) | 0.21 (0.19;0.23) | 0.20 (0.17;0.23) | 0.19 (0.17;0.22) ( | 0.19 (0.17;0.22) ( | −4.50 (−9.64,0.93) | 0.096 |
| Hyperemic flow (cm/s) | 0.71 ± 0.12 | 0.73 ± 0.12 | 0.62 ± 0.07 ( | 0.63 ± 0.08 ( | −0.46 (−5.38,4.95) | 0.886 |
| TDE-CFR | 3.44 ± 0.61 | 3.64 ± 0.53 | 3.28 ± 0.69 ( | 3.33 ± 0.68 ( | 4.95 (1.62,8.64) | 0.005 |
| LVEF rest (%) | 65 ± 8 | 64 ± 13 | 66 ± 8 | 65 ± 9 | −0.92 (−8.59,7.65) | 0.829 |
| Hyperemic LVEF (%) | 70 ± 5 | 75 ± 7 | 70 ± 7 ( | 68 ± 10 ( | 10.15 (19.40, 1.62) | 0.022 |
| HR rest (bpm) | 60 ± 10 | 55 ± 6 | 62 ± 12 | 57 ± 7 | −1.83 (−7.53, 4.23) | 0.539 |
| HR hyperemia (bpm) | 80 ± 16 | 77 ± 10 | 84 ± 17 ( | 77 ± 14 ( | 4.95 (−3.39,14.02) | 0.244 |
| CO rest (102) | 34 (25;34) | 33 (27;36) | 36 (33;47) | 37 (27;41) | −4.94 (−18.15,10.15) | 0.487 |
| Rate pressure product (bpm x mmHg x 102) | 73 (61;85) | 67 (56;75) | 70 (61;81) | 67 (62;76) | −4.06 (−10.67,3.28) | 0.270 |
| RHI | 2.44 (2.09;2.68) ( | 2.45 (2.12;3.01) ( | 2.41 (2.18;2.91) ( | 2.46 (2.12;3.25) ( | 2.09 (−12.70,19.40) | 0.749 |
| cbIMT (mm) | 1.05 (0.90;1.15) | 1.10 (1.00;1.20) | 1.00 (0.85;1.13) | 1.10 (0.85;1.10) | 4.47 (−3.39,12.98) | 0.268 |
| Carotid IMT (mm) | 0.64 (0.59;0.77) | 0.62 (0.57;0.72) | 0.61 (0.55;0.64) | 0.63 (0.54;0.66) | −4.28 (−9.84,1.62) | 0.145 |
Data are presented with mean ± SD or median ± interquartile range for normally distributed and non-normally distributed, respectively. Effect of DAPS adjusted for controls is presented as percentage change with 95% confidence intervals. cbIMT=carotid bifurcation intima-media thickness; CI = confidence interval; CO = cardiac output; HR = heart rate; IMT=intima media thickness; LVEF=left ventricle ejection fraction; RHI = reactive hyperemic index; TDE-CFR = transthoracic color Doppler echocardiography assessed coronary flow reserve.
Effect of personalized overall health program on clinical parameters and biomarkers in DAPS compared to controls using ANCOVA
| DAPS pre-exercise ( | DAPS post-exercise ( | Standard pre-control ( | Standard post-control = pre-exercise ( | Adjusted effect (%) (95% CI) | ||
|---|---|---|---|---|---|---|
| Body mass index (kg/m2) | 24.0 (23.0;24.3) | 23.0 (21.0;24.0) | 24.0 (23.0;25;0) | 24.0 (22.5;24.8) | −3.62 (−6.46,−0.69) | 0.017 |
| Waist/Hip ratio | 0.85 (0.79;0.89) ( | 0.82 (0.77;0.89) ( | 0.85 (0.81;0.90) ( | 0.85 (0.80;0.90) ( | −2.95 (−5.59,−0.09) | 0.044 |
| Fat percentage (%) | 29.9 (28.2;32.3) ( | 28.8 (26.7;30.9) ( | 29.6 (25.0;33.1) ( | 29.4 (25.7;33.7) ( | −5.16 (−8.59,−1.83) | 0.004 |
| hs-CRP (nmoL/L) | 3.81 (2.48;11.1) ( | 2.95 (0.76;10.9) ( | 6.57 (3.24;7.81) ( | 4.00 (2.76;7.33) ( | −23.62 (−59.45,43.55) | 0.390 |
| Cholesterol (mmol/L) | 5.4 ± 0.8 ( | 5.3 ± 0.8 ( | 5.5 ± 0.9 ( | 5.5 ± 0.8 ( | −4.28 (−8.80,0.69) | 0.088 |
| Triglycerides (mmol/L) | 0.73 (0.56;0.96) ( | 0.67 (0.60;0.98) ( | 0.86 (0.65;1.25) ( | 0.82 (0.61;1.14) ( | 3.99 (−9.64,19.40) | 0.573 |
| HDL (mmol/L) | 1.80 (1.60;2.08) ( | 1.80 (1.55;2.20) ( | 1.95 (1.43;2.28) ( | 1.80 (1.50;2.25) ( | 3.04 (−3.84,10.66) | 0.385 |
| Total leukocyte count (*109/L) | 5.70 (4.88;6.60) ( | 4.75 (4.90;6.60) ( | 5.05 (4.70;6.75) ( | 4.80 (4.25;5.60) ( | −4.28 (−17.40,10.92) | 0.549 |
| Platelet count (*109/L) | 219 (203;253) ( | 216 (181;229) ( | 226 (212;258) ( | 227 (212;261) ( | −12.30 (−19.65,−4.06) | 0.005 |
| Neutrophils (*109/L) | 2.95 (2.50;3.85) ( | 2.60 (1.80;3.30) ( | 2.85 (2.18;4.30) ( | 2.55 (2.10;3.30) ( | −7.32 (−26.38,16.68) | 0.507 |
| Fibrinogen (μmol/L) | 9.11 (8.38;11.3) ( | 8.23 (7.35;10.7) ( | 8.53 (8.23;10.0) ( | 8.53 (7.94;10.0) ( | −12.10 (−22.02,−0.92) | 0.035 |
| Fasting Glucose (mmol/L) | 5.2 ± 0.4 ( | 5.2 ± 0.4 ( | 5.3 ± 0.4 ( | 5.3 ± 0.3 ( | −1.60 (−5.38,2.33) | 0.419 |
| Insulin (pmol/L) | 32.6 (22.2;50.0) ( | 31.3 (25.0;43.8) ( | 32.0 (19.5;42.4) ( | 29.9 (16.0;39.6) ( | 21.62 (−10.05,64.06) | 0.193 |
| HOMA-IR | 1.1 (0.7;1.9) ( | 1.0 (0.8;1.4) ( | 1.0 (0.7;1.5) ( | 1.0 (0.5;1.4) ( | 18.85 (−13.90,64.06) | 0.279 |
| Quality of Life (% of max)* | 80 (72;83) | 83 (76;90) | 83 (80;87) ( | 83 (73;88) ( | 0.049 |
Data are presented with mean ± SD or median ± interquartile range for normally distributed and non-normally distributed, respectively. Effect of DAPS adjusted for controls is presented as percentage change with 95% confidence intervals. CI = confidence interval; HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; hs-CRP = high sensitivity C-reactive protein.
*Analyzed on delta change using Wilcoxon signed-rank test
Effect of personalized overall health program on clinical parameters and biomarkers in DAPS compared to a standard program using ANCOVA
| DAPS pre-exercise ( | DAPS post-exercise ( | Standard post-control = pre-exercise ( | Standard post-exercise ( | Adjusted effect (%) (95% CI) | p-value (adjusted effect) | |
|---|---|---|---|---|---|---|
| TDE-CFR | 3.44 ± 0.61 | 3.64 ± 0.53 | 3.33 ± 0.68 ( | 3.40 ± 0.62 ( | 3.99 (0.69,7.65) | 0.018 |
| Hyperemic LVEF (%) | 70 ± 5 | 75 ± 7 | 68 ± 10 ( | 67 ± 7 ( | 8.89 (1.62,16.68) | 0.017 |
| Body mass index (kg/m2) | 24.0 (23.0;24.3) | 23.0 (21.0;24.0) | 24.0 (22.5;24.8) | 23.0 (21.5;24.5) | −1.83 (−4.50,0.93) | 0.180 |
| Waist/Hip ratio | 0.85 (0.79;0.89) ( | 0.82 (0.77;0.89) ( | 0.85 (0.80;0.90) ( | 0.80 (0.76;0.87) ( | 1.16 (−2.28,4.95) | 0.497 |
| Fat percentage (%) | 29.9 (28.2;32.3) ( | 28.8 (26.7;30.9) ( | 29.4 (25.7;33.7) ( | 29.3 (24.8;32) ( | −2.05 (−5.59,1.39) | 0.222 |
| Platelet count (*109/L) | 219 (203;253) ( | 216 (181;229) ( | 227 (212;261) ( | 211 (197;256) ( | −2.50 (−10.05,5.68) | 0.540 |
| Fibrinogen (μmol/L) | 9.11 (8.38;11.3) ( | 8.23 (7.35;10.7) ( | 8.53 (7.94;10.0) ( | 8.82 (8.03;9.41) ( | −6.89 (−16.05,3.28) | 0.170 |
| Quality of life (%)* | 80 (72;83) | 83 (76;90) | 83 (73;88) ( | 89 (85;91) ( | 0.860 |
Data are presented with mean ± SD or median ± interquartile range for normally distributed and non-normally distributed, respectively. Effect of DAPS relative to standard program is presented as percentage change with 95% confidence intervals. LVEF = left ventricle ejection fraction; TDE-CFR = transthoracic color Doppler echocardiography assessed coronary flow reserve.
*Analyzed on delta change using Wilcoxon signed-rank test
Figure 1Recruitment and follow-up of study participants
CV=cardiovascular; DAPS=Diagnosis, Analysis, Personalization, Supervision.